BIOCRYST PHARMACEUTICALS INC — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Charles Gayer (CEO) and Babar Ghias (CFO) certified the Q3 2026 10-Q for the period ended September 30, 2026, filed November 4, 2026. Both officers attested to the accuracy of financial statements, effectiveness of disclosure controls and internal controls over financial reporting, and compliance with Exchange Act requirements. No material weaknesses, significant deficiencies, or fraud were disclosed.
Why this rating
Standard Sarbanes-Oxley certifications; boilerplate disclosure requirement with no operational, financial, or strategic content disclosed.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.